[Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].

Fuyuhiko Motoi, Kei Kawaguchi, Takeshi Aoki, Katsumasa Kudo, Shinichi Yabuuchi, Koji Fukase, Masamichi Mizuma, Naoaki Sakata, Shigeru Otsutomo, Takanori Morikawa, Hiroki Hayashi, Kei Nakagawa, Takaho Okada, Hiroshi Yoshida, Takeshi Naitoh, Yu Katayose, Shinichi Egawa, Michiaki Unno

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Surgery followed by adjuvant chemotherapy is standard care for resectable pancreatic carcinoma. The maximum estimated 2-year survival rate associated with this strategy is nearly 50%. The use of neoadjuvant therapy for pancreatic cancer remains controversial, and its efficacy has not been elucidated. To evaluate the efficacy of neoadjuvant chemotherapy for planned pancreatic cancer resection, the oncological outcomes of neoadjuvant gemcitabine plus S-1 combination therapy( GS therapy) and a surgery-first approach were retrospectively compared. Patients with planned pancreatic cancer resection and without major artery abutments were enrolled in this study. There were 39 cases of neoadjuvant GS therapy (N group) and 93 cases of the surgery-first approach( S group). Survival and surrogate markers, including the R0 rate, the "true R0 rate"( R0 with tumor marker normalization after resection), and N0 rate, were compared. The groups did not differ significantly in terms of age, gender, or tumor location. The resection rates of the N and S groups were similar (92% and 86%, respectively). The median survival of the N group (39.4 months) was significantly longer than that of the S group (20.8 months) in intention-to-treat analysis (p=0.0009). The R0, true R0, and N0 rates of the N group (85%, 69%, and 44%, respectively) were higher than those of the S group( 72%, 48%, and 24%, respectively). In conclusion, this retrospective analysis showed that neoadjuvant GS therapy might be more effective than the standard surgery-first strategy in terms of oncological outcomes for resectable pancreatic cancer. A prospective randomized study, Prep-02/JSAP-05, which compares neoadjuvant therapy to the surgery-first approach, is ongoing (UMIN-No. 000009634).

Original languageEnglish
Pages (from-to)1632-1636
Number of pages5
JournalUnknown Journal
Volume40
Issue number12
Publication statusPublished - 2013 Nov

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '[Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].'. Together they form a unique fingerprint.

  • Cite this

    Motoi, F., Kawaguchi, K., Aoki, T., Kudo, K., Yabuuchi, S., Fukase, K., Mizuma, M., Sakata, N., Otsutomo, S., Morikawa, T., Hayashi, H., Nakagawa, K., Okada, T., Yoshida, H., Naitoh, T., Katayose, Y., Egawa, S., & Unno, M. (2013). [Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma]. Unknown Journal, 40(12), 1632-1636.